Oxford Innovation EIS Growth Fund has backed the manufacturer of cold corrugation equipment in a follow-on funding round.
"Despite appearances, corrugated board is not easy to make and over the last 50 years there has been little to no innovation in the manufacturing process. With the majority of global goods now being bought online and demand for sustainable packaging increasing, it was time for a revolutionary solution to the current energy and water intensive manufacturing processes. Our cold corrugation process uses 80% less energy, is one tenth of the price, and allows for decentralised, on-demand production that reduces manufacturing costs by up to 30%. This recent investment will allow us to continue the manufacture of our innovative machines and enable more customers to harness the benefits of self-manufacturing their corrugated board more sustainably."
The funding was backed by the UK Innovation & Science Seed Fund, Oxford Innovation EIS Growth Fund, Oxford Innovation Finance's Angel Network, and the Defence and Security Accelerator.
"This new investment provides us with the funding to take our game changing technology to commercialisation, helping deliver the UK government’s semiconductor and technology strategy. Our Inertial sensors are already gaining strong industry interest globally with a major aerospace and defence contractor having already placed contracts. Our revolutionary gravity sensor will be commercialised later this year with the industry interest shown by our acceptance on to Europe’s largest infrastructure accelerator program and the award of funding from the Department for Business and Trade railway construction innovation competition. We are very excited for this next stage in SMG’s journey."
— Francis Neill, Chief Executive Officer and Director
Oxford Innovation and OION angels have backed Cognitant Group in a follow-on funding round.
"We are focused on making it easier for patients to understand their symptoms and management of their individual condition. This not only has a positive impact on their overall health, but it also allows them to successfully make decisions about their individual treatment plans in collaboration with their clinicians. Our partnerships with global pharmaceutical companies, the NHS and other healthcare providers, is making real and valuable changes to the way patients engage with and manage their health."
The oversubscribed round will scale up manufacturing and research for the bioactive protein developer.
"We are at an exciting stage of development, with new funds facilitating our next phase of rapid growth as we continue our mission of providing more reliable tools for research and bio-manufacturing. Our platform provides an improved process for complex protein manufacture at exceptionally high purity and unique engineered products that address specific challenges for stem cell biology. Growth factors are essential reagents for all stem cell manufacturing, and therefore critical for the delivery of cell therapies and cultivated meats."
The funding round was supported by Oxford Innovation EIS Growth Fund and OION Angels.
"This new funding allows EcoSync to make significant progress towards the next milestones in its development strategy, giving us the opportunity to expand into other sectors and accelerate growth. Without the support of our new, and existing, investors we would not have been able to make such compelling advancements and take our solution to market, where it can have a real impact in driving a transition towards net zero carbon."
